SG11202109399SA - Rad51 inhibitors - Google Patents
Rad51 inhibitorsInfo
- Publication number
- SG11202109399SA SG11202109399SA SG11202109399SA SG11202109399SA SG11202109399SA SG 11202109399S A SG11202109399S A SG 11202109399SA SG 11202109399S A SG11202109399S A SG 11202109399SA SG 11202109399S A SG11202109399S A SG 11202109399SA SG 11202109399S A SG11202109399S A SG 11202109399SA
- Authority
- SG
- Singapore
- Prior art keywords
- rad51 inhibitors
- rad51
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962816998P | 2019-03-12 | 2019-03-12 | |
| PCT/US2020/022293 WO2020186006A1 (en) | 2019-03-12 | 2020-03-12 | Rad51 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202109399SA true SG11202109399SA (en) | 2021-09-29 |
Family
ID=72422797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202109399SA SG11202109399SA (en) | 2019-03-12 | 2020-03-12 | Rad51 inhibitors |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11247988B2 (en) |
| EP (1) | EP3938358A4 (en) |
| JP (1) | JP7460649B2 (en) |
| KR (1) | KR20210127790A (en) |
| CN (1) | CN114072390A (en) |
| AU (1) | AU2020235089A1 (en) |
| BR (1) | BR112021017336A2 (en) |
| CA (1) | CA3132987A1 (en) |
| IL (1) | IL285889A (en) |
| MX (1) | MX2021010916A (en) |
| SG (1) | SG11202109399SA (en) |
| TW (1) | TW202104198A (en) |
| WO (1) | WO2020186006A1 (en) |
| ZA (1) | ZA202106284B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019014315A1 (en) | 2017-07-11 | 2019-01-17 | Cyteir Therapeutics, Inc. | Rad51 inhibitors |
| JP7265537B2 (en) | 2017-09-11 | 2023-04-26 | サイティアー セラピューティクス，インコーポレイティド | RAD51 inhibitor |
| JP7460649B2 (en) | 2019-03-12 | 2024-04-02 | サイティアー セラピューティクス，インコーポレイティド | RAD51 inhibitor |
| CA3133005A1 (en) | 2019-03-25 | 2020-10-01 | Cyteir Therapeutics, Inc. | Combinations of rad51 and parp inhibitors |
| EP4108663A1 (en) * | 2020-02-19 | 2022-12-28 | Simcere Pharmaceutical Co., Ltd. | Substituted aryl compound |
| CN116063243A (en) * | 2021-11-02 | 2023-05-05 | 上海旭成医药科技有限公司 | Aromatic compound, preparation method, intermediate, pharmaceutical composition and application thereof |
| WO2023185831A1 (en) * | 2022-03-29 | 2023-10-05 | 正大天晴药业集团股份有限公司 | Compound containing thiazole ring |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| JPS6230780A (en) | 1985-04-17 | 1987-02-09 | Ss Pharmaceut Co Ltd | Naphthyridine derivative and pharmaceutical containing said derivative |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| WO1992010588A1 (en) | 1990-12-06 | 1992-06-25 | Affymax Technologies N.V. | Sequencing by hybridization of a target nucleic acid to a matrix of defined oligonucleotides |
| US5837832A (en) | 1993-06-25 | 1998-11-17 | Affymetrix, Inc. | Arrays of nucleic acid probes on biological chips |
| US6309823B1 (en) | 1993-10-26 | 2001-10-30 | Affymetrix, Inc. | Arrays of nucleic acid probes for analyzing biotransformation genes and methods of using the same |
| GB9507238D0 (en) | 1995-04-07 | 1995-05-31 | Isis Innovation | Detecting dna sequence variations |
| WO2012113774A1 (en) | 2011-02-24 | 2012-08-30 | Nerviano Medical Sciences S.R.L. | Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors |
| EA201791271A1 (en) | 2012-05-31 | 2018-01-31 | Фенекс Фармасьютикалз Аг | THIAZOLES, SUBSTITUTED BY CARBOXAMIDE OR SULPHONAMIDE AND RELATED DERIVATIVES AS MODULATORS FOR ORPHANIC NUCLEAR RORγ RECEPTOR |
| JP2017100949A (en) | 2014-04-01 | 2017-06-08 | 大日本住友製薬株式会社 | 5-membered heteroaryl derivative |
| TW201702218A (en) | 2014-12-12 | 2017-01-16 | 美國杰克森實驗室 | Compositions and methods relating to the treatment of cancer, autoimmune disease, and neurodegenerative disease |
| WO2016140971A1 (en) | 2015-03-02 | 2016-09-09 | The Regents Of The University Of California | Novel rad51 inhibitors and uses thereof |
| WO2016196955A1 (en) * | 2015-06-04 | 2016-12-08 | Drexel University | Inhibitors of RAD52 Recombination Protein and Methods Using Same |
| WO2019014315A1 (en) | 2017-07-11 | 2019-01-17 | Cyteir Therapeutics, Inc. | Rad51 inhibitors |
| JP7265537B2 (en) | 2017-09-11 | 2023-04-26 | サイティアー セラピューティクス，インコーポレイティド | RAD51 inhibitor |
| JP7460649B2 (en) | 2019-03-12 | 2024-04-02 | サイティアー セラピューティクス，インコーポレイティド | RAD51 inhibitor |
| CA3133005A1 (en) | 2019-03-25 | 2020-10-01 | Cyteir Therapeutics, Inc. | Combinations of rad51 and parp inhibitors |
-
2020
- 2020-03-12 JP JP2021553834A patent/JP7460649B2/en active Active
- 2020-03-12 BR BR112021017336A patent/BR112021017336A2/en unknown
- 2020-03-12 WO PCT/US2020/022293 patent/WO2020186006A1/en unknown
- 2020-03-12 KR KR1020217032591A patent/KR20210127790A/en unknown
- 2020-03-12 CA CA3132987A patent/CA3132987A1/en active Pending
- 2020-03-12 US US16/816,393 patent/US11247988B2/en active Active
- 2020-03-12 EP EP20768883.9A patent/EP3938358A4/en active Pending
- 2020-03-12 TW TW109108203A patent/TW202104198A/en unknown
- 2020-03-12 MX MX2021010916A patent/MX2021010916A/en unknown
- 2020-03-12 SG SG11202109399SA patent/SG11202109399SA/en unknown
- 2020-03-12 CN CN202080035279.0A patent/CN114072390A/en active Pending
- 2020-03-12 AU AU2020235089A patent/AU2020235089A1/en active Pending
-
2021
- 2021-08-26 IL IL285889A patent/IL285889A/en unknown
- 2021-08-30 ZA ZA2021/06284A patent/ZA202106284B/en unknown
- 2021-12-16 US US17/552,577 patent/US11932636B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020235089A1 (en) | 2021-09-23 |
| US20220259198A1 (en) | 2022-08-18 |
| US11247988B2 (en) | 2022-02-15 |
| EP3938358A4 (en) | 2022-12-21 |
| CA3132987A1 (en) | 2020-09-17 |
| WO2020186006A1 (en) | 2020-09-17 |
| ZA202106284B (en) | 2023-02-22 |
| KR20210127790A (en) | 2021-10-22 |
| BR112021017336A2 (en) | 2021-11-09 |
| IL285889A (en) | 2021-10-31 |
| JP7460649B2 (en) | 2024-04-02 |
| JP2022525069A (en) | 2022-05-11 |
| TW202104198A (en) | 2021-02-01 |
| US20200291014A1 (en) | 2020-09-17 |
| CN114072390A (en) | 2022-02-18 |
| EP3938358A1 (en) | 2022-01-19 |
| MX2021010916A (en) | 2021-10-01 |
| US11932636B2 (en) | 2024-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202106520VA (en) | Kif18a inhibitors | |
| ZA202104029B (en) | Rad51 inhibitors | |
| ZA202106284B (en) | Rad51 inhibitors | |
| SG11202008113RA (en) | Arginase inhibitors | |
| IL287767A (en) | Cdk inhibitors | |
| EP3817736A4 (en) | Pikfyve inhibitors | |
| IL289914A (en) | Enzyme inhibitors | |
| IL289863A (en) | Enzyme inhibitors | |
| SG11202006453SA (en) | Pi4kiiibeta inhibitors | |
| IL289783A (en) | Enzyme inhibitors | |
| IL289778A (en) | Enzyme inhibitors | |
| GB201907882D0 (en) | Methods | |
| IL281514A (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | |
| EP3976797A4 (en) | Anti-crispr inhibitors | |
| GB201913716D0 (en) | Methods | |
| EP4081199A4 (en) | Lipoxygenase inhibitors | |
| GB201906705D0 (en) | Methods | |
| GB201903909D0 (en) | Methods | |
| GB201901817D0 (en) | Methods | |
| GB201908044D0 (en) | Dopamine-B-Hydroxylase inhibitors | |
| GB201905476D0 (en) | MAPA4K4 Inhibitors | |
| IL292104A (en) | Egfr inhibitors | |
| EP4076665C0 (en) | Egfr inhibitors | |
| ZA202108775B (en) | New egfr inhibitors | |
| GB201812462D0 (en) | Inhibitors |